chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Cardiac enzymes, Chest pain, Echocardiogram, Electrocardiogram, Myopericarditis
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Nuclear magnetic resonance imaging, Pericarditis
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Echocardiogram abnormal, Electrocardiogram abnormal, Lumbar puncture normal, Pericardial disease, Troponin I
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Abdominal pain, Abdominal rigidity, Abdominal tenderness, Activated partial thromboplastin time normal, Activated partial thromboplastin time shortened
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Adenovirus test, Albumin globulin ratio, Anaemia, Angiogram, Anti-cyclic citrullinated peptide antibody negative
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Antinuclear antibody negative, Aspartate aminotransferase increased, Asthenia, Atelectasis, Atrial septal defect
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Back pain, Bilirubin conjugated increased, Blood albumin decreased, Blood alkaline phosphatase normal, Blood creatine phosphokinase MB increased
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Blood creatine phosphokinase decreased, Blood culture negative, Blood thyroid stimulating hormone normal, Blood urea increased, Brain natriuretic peptide normal
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: C-reactive protein increased, CSF glucose normal, CSF lymphocyte count, CSF monocyte count, CSF protein normal
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: CSF white blood cell count negative, Cardiomegaly, Chest X-ray abnormal, Chest discomfort, Chest pain
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Chills, Clostridium test negative, Cold sweat, Computerised tomogram abdomen abnormal, Computerised tomogram pelvis abnormal
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Computerised tomogram thorax abnormal, Coxsackie virus test negative, Dyspnoea, Echocardiogram abnormal, Echovirus test negative
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Ejection fraction decreased, Electrocardiogram ST segment abnormal, Electrocardiogram T wave abnormal, Electrocardiogram T wave inversion, Fibrin D dimer decreased
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Generalised oedema, Globulins increased, HIV test negative, Haematocrit decreased, Haemoglobin decreased
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Headache, Hepatic steatosis, Hepatosplenomegaly, Hyperhidrosis, Injection site erythema
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Injection site swelling, International normalised ratio normal, Laboratory test normal, Leukocytosis, Lipase normal
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Lymph node pain, Lymphadenopathy, Lymphocyte percentage decreased, Malaise, Metabolic function test normal
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Mitral valve incompetence, Monocyte percentage increased, Myocardial necrosis marker, Nausea, Neck pain
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Neutrophil percentage increased, Night sweats, Nuclear magnetic resonance imaging heart, Pain, Painful respiration
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Pericardial effusion, Pericarditis, Phonophobia, Photophobia, Pleural effusion
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Protein total increased, Prothrombin time prolonged, Pyrexia, Red blood cell count decreased, Red blood cell sedimentation rate increased
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Red cell distribution width increased, Serum ferritin increased, Sinus bradycardia, Thyroxine free normal, Tricuspid valve incompetence
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Troponin I normal, Troponin normal, Tuberculin test negative, Ultrasound abdomen abnormal, Urine analysis normal
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Viral infection, White blood cell count increased
Clinical narrative: This case was received on 09 December 2010 via a third party query tool search on the VAERS database, under reference number 401759. A 19-year-old male patient, who had no concurrent illnesses or medical history, had received the following vaccinations on 27 July 2010: ACAM2000 (lot number VV04-003-A), HAVRIX (GlaxoSmithKline, lot number AHAVB408BA), and FLUMIST (Medimmune, lot number 501045P). Ten days post-vaccination on 06 August 2010 the patient experienced chest pain that was found to be myopericarditis and was hospitalized and initially treated with NSAIDS. The patient was subsequently readmitted for pericarditis and treated with NSAIDS and Colchicine which the patient was intolerant to. The patient was again subsequently readmitted for pericarditis and treated with high dose ASA and low dose colchicine. Diagnostic tests that were completed included: ECHO, cardiac MR, EKG and cardiac enzymes; however results were not reported. The patient's recovery status was not reported. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Cardiac enzymes, Chest pain, Echocardiogram, Electrocardiogram, Myopericarditis
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Nuclear magnetic resonance imaging, Pericarditis
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Echocardiogram abnormal, Electrocardiogram abnormal, Lumbar puncture normal, Pericardial disease, Troponin I
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Abdominal pain, Abdominal rigidity, Abdominal tenderness, Activated partial thromboplastin time normal, Activated partial thromboplastin time shortened
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Adenovirus test, Albumin globulin ratio, Anaemia, Angiogram, Anti-cyclic citrullinated peptide antibody negative
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Antinuclear antibody negative, Aspartate aminotransferase increased, Asthenia, Atelectasis, Atrial septal defect
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Back pain, Bilirubin conjugated increased, Blood albumin decreased, Blood alkaline phosphatase normal, Blood creatine phosphokinase MB increased
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Blood creatine phosphokinase decreased, Blood culture negative, Blood thyroid stimulating hormone normal, Blood urea increased, Brain natriuretic peptide normal
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: C-reactive protein increased, CSF glucose normal, CSF lymphocyte count, CSF monocyte count, CSF protein normal
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: CSF white blood cell count negative, Cardiomegaly, Chest X-ray abnormal, Chest discomfort, Chest pain
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Chills, Clostridium test negative, Cold sweat, Computerised tomogram abdomen abnormal, Computerised tomogram pelvis abnormal
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Computerised tomogram thorax abnormal, Coxsackie virus test negative, Dyspnoea, Echocardiogram abnormal, Echovirus test negative
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.
Age: 19.0
Sex: M
Vaccine: FLUN3, HEPA, SMALL, ANTH, HEPA, SMALL, ANTH, HEPA, SMALL, FLUN3, HEPA, SMALL
Symptoms: Ejection fraction decreased, Electrocardiogram ST segment abnormal, Electrocardiogram T wave abnormal, Electrocardiogram T wave inversion, Fibrin D dimer decreased
Clinical narrative: This study case was received from the investigator in a trial on 06 June 2011. A 19 year-old male subject with no significant medical history was found to have an unspecified disease of the pericardium 18 days after he had received an injection of ACAM2000 (lot number, route and site of administration not reported), Anthrax 1 (manufacturer, lot number, route and site of administration not reported) and Hepatitis A Adult (manufacturer, lot number, route and site of administration not reported) on 27 July 2010. Relevant laboratory data included: a normal Troponin I result, an abnormal ECG, an abnormal Echocardiogram and a normal lumbar puncture (spinal tap). Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: there is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Follow-up information was received on 24 August 2011 via a third party query tool search on the VAERS database, under reference number 425440. No further information was provided at the time of the report. Documents held by sender: none.